{"id":"https://openalex.org/W1908117496","doi":"https://doi.org/10.1111/dom.12312","title":"The dipeptidyl peptidase\u20104 inhibitor linagliptin lowers postprandial glucose and improves measures of \u03b2 \u2010cell function in type 2 diabetes","display_name":"The dipeptidyl peptidase\u20104 inhibitor linagliptin lowers postprandial glucose and improves measures of \u03b2 \u2010cell function in type 2 diabetes","publication_year":2014,"publication_date":"2014-05-13","ids":{"openalex":"https://openalex.org/W1908117496","doi":"https://doi.org/10.1111/dom.12312","mag":"1908117496","pmid":"https://pubmed.ncbi.nlm.nih.gov/24821586"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12312","doi":"https://doi.org/10.1111/dom.12312","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12312","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1908117496"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065775242","display_name":"Tim Heise","orcid":"https://orcid.org/0000-0002-8346-2037","observed_orcids":["https://orcid.org/0000-0002-8346-2037"]},"institutions":[{"id":"https://openalex.org/I4210165534","display_name":"Profil Institute for Metabolic Research","ror":"https://ror.org/05krxy197","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210165534"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"T. Heise","raw_affiliation_strings":["Profil Institut f\u00fcr Stoffwechselforschung GmbH  Neuss Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profil Institut f\u00fcr Stoffwechselforschung GmbH  Neuss Germany","institution_ids":["https://openalex.org/I4210165534"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050340100","display_name":"Martin Larbig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"M. Larbig","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000118493","display_name":"Sakshi Patel","orcid":"https://orcid.org/0009-0000-2041-9325","observed_orcids":["https://orcid.org/0009-0000-2041-9325"]},"institutions":[{"id":"https://openalex.org/I4210112752","display_name":"Boehringer Ingelheim (United Kingdom)","ror":"https://ror.org/01jnnpe14","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210112752"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Patel","raw_affiliation_strings":["Boehringer Ingelheim Ltd., Bracknell, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Ltd., Bracknell, UK","institution_ids":["https://openalex.org/I4210112752"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110110990","display_name":"Thomas L. Seck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"T. Seck","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025609173","display_name":"Uwe Hehnke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"U. Hehnke","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056064349","display_name":"Hans Juergen Woerle","orcid":"https://orcid.org/0000-0003-2595-1411","observed_orcids":["https://orcid.org/0000-0003-2595-1411"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"H.\u2010J. Woerle","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111521277","display_name":"Klaus A. Dugi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"K. Dugi","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5065775242"],"corresponding_institution_ids":["https://openalex.org/I4210165534"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":1.7038,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.82761209,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"16","issue":"10","first_page":"1036","last_page":"1039"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/linagliptin","display_name":"linagliptin","score":1.0},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9739999771118164},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.7960000038146973},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.9909999966621399},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8939999938011169},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9210000038146973},{"id":"https://openalex.org/keywords/homa-beta","display_name":"HOMA-\u03b2","score":0.9070000052452087},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8379999995231628}],"concepts":[{"id":"https://openalex.org/C2780031085","wikidata":"https://www.wikidata.org/wiki/Q909745","display_name":"Linagliptin","level":4,"score":0.9964298605918884},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.8790602684020996},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8412958383560181},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.7789550423622131},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7524610161781311},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5971484184265137},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5771665573120117},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5171512961387634},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4989449977874756},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.45912420749664307},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4468907117843628},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3932933211326599},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3602048456668854},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.04479551315307617},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069476","descriptor_name":"Linagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005947","descriptor_name":"Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019518","descriptor_name":"Postprandial Period","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050417","descriptor_name":"Insulin-Secreting Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D050417","descriptor_name":"Insulin-Secreting Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/dom.12312","doi":"https://doi.org/10.1111/dom.12312","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12312","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:24821586","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24821586","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307779","display_name":"Roche","ror":"https://ror.org/00by1q217"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1968236091","https://openalex.org/W2058885439","https://openalex.org/W2064437324","https://openalex.org/W2089095955","https://openalex.org/W2111473023","https://openalex.org/W2116385513","https://openalex.org/W2116492775","https://openalex.org/W2118830784","https://openalex.org/W2124020657","https://openalex.org/W2124620553","https://openalex.org/W2127409471","https://openalex.org/W2149413273","https://openalex.org/W2752336761"],"related_works":["https://openalex.org/W2140480989","https://openalex.org/W1771498646","https://openalex.org/W2115574356","https://openalex.org/W2745038773","https://openalex.org/W1978432888","https://openalex.org/W2072114549","https://openalex.org/W3199347403","https://openalex.org/W2601098938","https://openalex.org/W4205965838","https://openalex.org/W2810670609"],"abstract_inverted_index":{"Progressive":[0],"deterioration":[1],"of":[2,17,23,36,44,47,98],"pancreatic":[3],"\u03b2-cell":[4,30,100,147],"function":[5,31],"in":[6,52,70,137,146],"patients":[7,54],"with":[8,55,105,111,139],"type":[9],"2":[10],"diabetes":[11],"mellitus":[12],"(T2DM)":[13],"contributes":[14],"to":[15,131],"worsening":[16],"hyperglycaemia.":[18],"To":[19],"investigate":[20],"the":[21,24,134],"effects":[22],"dipeptidyl":[25],"peptidase-4":[26],"inhibitor":[27],"linagliptin":[28,48,83,140],"on":[29],"parameters,":[32],"a":[33,95],"pooled":[34],"analysis":[35],"six":[37],"randomized,":[38],"24-week,":[39],"placebo-controlled,":[40],"phase":[41],"3":[42],"trials":[43],"5":[45],"mg":[46],"daily":[49],"was":[50,102],"performed":[51],"2701":[53],"T2DM":[56],"(linagliptin,":[57],"n":[58,62],"=":[59,63,125],"1905;":[60],"placebo,":[61],"796).":[64],"At":[65],"week":[66],"24,":[67],"observed":[68],"improvements":[69,145],"HbA1c,":[71],"fasting":[72,99],"plasma":[73],"glucose,":[74],"and":[75,107],"2-h":[76],"postprandial":[77],"glucose":[78],"were":[79],"significantly":[80,103],"greater":[81],"for":[82,118],"than":[84],"placebo":[85,112],"(all":[86],"p":[87,124],"<":[88],"0.0001).":[89],"Homeostasis":[90],"model":[91],"assessment":[92],"(HOMA)-%\u03b2,":[93],"as":[94],"surrogate":[96],"marker":[97],"function,":[101],"improved":[104],"linagliptin,":[106],"did":[108],"not":[109],"change":[110,117],"(placebo-adjusted":[113],"mean":[114],"\u00b1":[115,121],"s.e.":[116],"linagliptin:":[119],"16.5":[120],"4.6":[122],"(mU/l)/(mmol/l);":[123],"0.0003).":[126],"Further":[127],"study":[128],"is":[129],"required":[130],"determine":[132],"if":[133],"significant":[135],"improvement":[136],"HOMA-%\u03b2":[138],"will":[141],"translate":[142],"into":[143],"long-term":[144],"function.":[148]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}